At a Glance
75/50 mg
BIC / LEN
Once daily
After 2-day initiation
<50
HIV-1 RNA copies/mL required
No NRTI
Conventional backbone
- No conventional NRTI backbone.
- Required baseline: stable ART and no known/suspected resistance to bictegravir or lenacapavir.
FDA Indication — Read First
THIS IS A SWITCH REGIMEN FOR ALREADY-SUPPRESSED ADULTS.
Bixlenvo is not approved here as untreated HIV therapy, treatment initiation for ART-naive patients, or a regimen for unsuppressed HIV. Historical resistance still matters: patients with known or suspected resistance to either component are outside the labeled use.
What Is Bixlenvo?
Bictegravir 75 mg
Integrase strand transfer inhibitor (INSTI). Inhibits HIV integrase and belongs to an established high-barrier antiretroviral class.
Lenacapavir 50 mg
HIV-1 capsid inhibitor. A first-in-class mechanism acting at multiple stages of the HIV lifecycle, with no expected class cross-resistance with existing antiretroviral classes.
Combination: INSTI + capsid inhibitor
Backbone: no tenofovir, emtricitabine, lamivudine, or abacavir
Role: maintenance switch
Dosing — Important Two-Day Initiation
Day 1
Bixlenvo 75 mg/50 mg1 tablet POplus Sunlenca (lenacapavir) 600 mg PO = two 300-mg tabletsDay 2
Bixlenvo 75 mg/50 mg1 tablet POplus Sunlenca (lenacapavir) 600 mg PO = two 300-mg tabletsDay 3 and thereafter
Bixlenvo 75 mg/50 mg1 tablet PO once daily- May be taken with or without food.
- Bixlenvo is a complete regimen; coadministration with other HIV-1 antiretroviral treatment is not recommended except for the labeled initiation doses of oral Sunlenca (lenacapavir).
Sunlenca context: lenacapavir is also labeled separately as a long-acting capsid inhibitor used with other antiretrovirals, with injection-based maintenance. In Bixlenvo, Sunlenca shows up only as the short oral initiation add-on for Days 1 and 2.
Missed Doses
- Missed initiation dose: take the missed Bixlenvo or Sunlenca (lenacapavir) initiation dose as soon as possible. Do not take both Day 1 and Day 2 Sunlenca doses on the same day.
- Missed maintenance dose: take Bixlenvo as soon as possible.
- More than 7 days since the last maintenance dose: if continuing Bixlenvo is clinically appropriate, restart the initiation regimen beginning with Day 1.
Who May Benefit Most?
- Already-suppressed adults who need regimen simplification.
- Patients on complex or multi-tablet antiretroviral therapy.
- Patients with historical resistance, tolerability barriers, drug interactions, or renal/bone considerations that limit conventional single-tablet options.
- Patients for whom avoiding a conventional NRTI backbone is clinically useful, such as a suppressed patient where tenofovir, emtricitabine, lamivudine, or abacavir are poor fits because of prior intolerance, resistance history, renal/bone context, cardiovascular-risk concerns, or other clinically appropriate reasons.
Resistance history still matters. Bixlenvo should not be used when resistance to bictegravir or lenacapavir is known or suspected.
HBV clarification: Bixlenvo does not provide HBV-active therapy. Patients with HIV/HBV coinfection require continued appropriate HBV treatment when switching ART.
Phase 3 Evidence ARTISTRY-1 & ARTISTRY-2
ARTISTRY-1
- Extensively treatment-experienced, virologically suppressed adults on complex ART.
- Median age 60 years; median prior ART exposure 28 years.
- Baseline pill burden 2-11 pills/day; about 40% used ART more than once daily.
- 67% had historical NRTI resistance.
ARTISTRY-2
- Virologically suppressed adults switching from Biktarvy to bictegravir/lenacapavir.
- Switching to bictegravir/lenacapavir was noninferior to continuing Biktarvy for maintenance of virologic suppression at Week 48.
- HIV-1 RNA ≥50 copies/mL at Week 48: 1.3% with BIC/LEN vs 1.0% with Biktarvy; prespecified noninferiority criterion met.
- Generally well tolerated in the clinical program.
Safety & Specific Populations
Common adverse reactions
- Headache — 4%
- Nausea — 3%
- Diarrhea — 2%
Pregnancy / lactation
- Lower bictegravir exposures have been observed during pregnancy with bictegravir-containing therapy; if used during pregnancy, monitor HIV viral load closely.
- The Antiretroviral Pregnancy Registry is available.
- Counsel patients with HIV-1 about breastfeeding according to current guidance and prescribing information.
Drug-Interaction Actions
Contraindicated / do not coadminister
- Dofetilide: contraindicated because bictegravir can increase dofetilide exposure, raising risk for serious dofetilide toxicity.
- Strong CYP3A inducers: do not coadminister because they may lower bictegravir/lenacapavir exposure and risk treatment failure or resistance. Label examples include carbamazepine, phenytoin, rifampin, and St. John's wort.
Not recommended
- Moderate CYP3A inducers: oxcarbazepine, phenobarbital, rifabutin, and rifapentine are not recommended because exposure may fall.
- Other HIV-1 antiretroviral treatment: Bixlenvo is a complete regimen; coadministration is not recommended except for the labeled oral Sunlenca initiation doses.
- Combined P-gp, UGT1A1, and strong CYP3A inhibitors: not recommended because bictegravir/lenacapavir exposure may rise. Atazanavir/cobicistat is the key studied example with a large lenacapavir exposure increase.
- Ergot derivatives, naloxegol, and tadalafil for pulmonary arterial hypertension: avoid or use an alternative when possible; if naloxegol cannot be avoided, decrease the naloxegol dose and monitor for adverse reactions.
Actionable checks before switching
- Aluminum/magnesium antacids: take Bixlenvo at least 2 hours before or 6 hours after.
- Calcium or iron supplements/antacids: take with food if given together; avoid routine fasting coadministration with, or 2 hours after, calcium/iron products. In pregnancy, if fasting, separate by at least 2 hours before or 6 hours after.
- Digoxin: use caution and monitor digoxin concentrations.
- Lovastatin/simvastatin: start with the lowest dose, titrate carefully, and monitor for myopathy.
- Metformin and DOACs: check the concomitant-drug prescribing information for benefit/risk, dosing, and monitoring.
- CYP3A-metabolized opioids, tramadol, buprenorphine, and methadone: monitor for clinical effect and toxicity; tramadol or opioid-dependence therapy dose adjustment may be needed.
- Oral midazolam/triazolam: use caution because exposure may increase.
- Voriconazole: studied PK effects do not translate into a clinically significant Bixlenvo interaction in the PI; do not extrapolate this into a blanket azole warning.
Do a complete medication-interaction review before switching. Do not rely only on the patient's existing ART interaction screen; lenacapavir changes the interaction profile.
Bixlenvo vs Biktarvy — Quick Orientation
| Bixlenvo | Biktarvy | |
|---|---|---|
| Components | bictegravir + lenacapavir | bictegravir + emtricitabine + tenofovir alafenamide |
| Classes | INSTI + capsid inhibitor | INSTI + 2 NRTIs |
| NRTI backbone | No | Yes |
| FDA population highlighted here | suppressed adults switching stable ART | broader HIV treatment indication |
| Initial supplemental dosing | Yes — oral Sunlenca (lenacapavir) Days 1-2 | No comparable initiation step |
| Maintenance | once daily | once daily |
Orientation only; this table does not imply clinical superiority.
Place in Therapy — Where Does Bixlenvo Fit?
Bixlenvo expands the oral single-tablet switch landscape rather than replacing established first-line ART. Its clearest niche is simplification of therapy in an already-suppressed adult when conventional single-tablet options are limited by regimen complexity, resistance history, tolerability, drug interactions, or backbone considerations.
| Regimen | Composition / Daily Form | Usual Place in Therapy | Main Advantages | Key Limitations / Cautions |
|---|---|---|---|---|
| Biktarvy | BIC/FTC/TAF; 1 tablet daily | Major guideline-recommended initial regimen for most adults and a common switch regimen. | BIC/FTC/TAF provides a high-resistance-barrier, unboosted daily option with HBV activity. | |
| Dovato | DTG/3TC; 1 tablet daily | Guideline-recommended 2-drug initial option for selected patients; also used for simplification/switching when eligibility is clear | Simple 2-drug regimen; avoids tenofovir; high-barrier dolutegravir; no booster | Not appropriate for HIV/HBV coinfection, HIV RNA >500,000 copies/mL, or when ART must begin before HIV genotype/HBV results are available. |
| Bixlenvo | BIC/LEN; 1 tablet daily after 2-day oral lenacapavir initiation | New maintenance switch option for virologically suppressed adults, especially when regimen complexity, prior resistance, tolerability, interactions, or NRTI-backbone limitations make existing STRs hard to use | Distinct INSTI + capsid-inhibitor combination; no tenofovir, FTC, 3TC, abacavir, or booster; no food requirement; potentially important simplification option for treatment-experienced patients | Not initial therapy and not for viremic patients; requires suppression and no known/suspected BIC or LEN resistance; does not provide HBV-active therapy; continue appropriate HBV treatment if HIV/HBV coinfection is present. Renal/hepatic: no dose adjustment with CrCl ≥15 mL/min or Child-Pugh A/B; not studied in ESRD with CrCl <15 mL/min or Child-Pugh C. |
| Idvynso | DOR/ISL; 1 tablet daily | New maintenance switch option for virologically suppressed adults. | Two-drug, tenofovir-free and non-INSTI STR; islatravir is an NRTI, so this is not an NRTI-sparing regimen. | Switch therapy, not initial therapy; assess prior virologic failure and doravirine resistance; no HBV-active backbone; strong CYP3A induction is contraindicated. |
| Juluca | DTG/RPV; 1 tablet daily with a meal | Established 2-drug maintenance/simplification option for suppressed adults | Long-established NRTI-sparing switch strategy; avoids tenofovir and abacavir | Must be taken with a meal; PPIs contraindicated with oral rilpivirine; H2 blockers/antacids require timing; no HBV treatment; historical NNRTI/INSTI resistance matters. |
| Delstrigo | DOR/3TC/TDF; 1 tablet daily | Alternative initial regimen when an NNRTI-based strategy is appropriate | One-tablet regimen; TDF/3TC provides HBV activity; no booster | TDF renal/bone considerations; strong CYP3A inducers are problematic; lower resistance barrier than second-generation INSTI-based regimens. |
| Symtuza | DRV/COBI/FTC/TAF; 1 tablet daily with food | Alternative initial/switch option when a darunavir-based high-resistance-barrier strategy is useful | Strong darunavir resistance barrier; useful when resistance or adherence concerns make a boosted protease-inhibitor regimen attractive | Cobicistat creates substantial DDI burden and affects serum-creatinine interpretation; food required; more interaction-heavy than unboosted INSTI options. |
| Genvoya | EVG/COBI/FTC/TAF; 1 tablet daily with food | Established/legacy STR often continued in stable patients rather than newly preferred | Convenient STR; FTC/TAF provides HBV activity | Cobicistat DDIs; food requirement; elvitegravir has a lower resistance barrier than BIC/DTG and has generally been displaced by newer unboosted INSTI options for many patients. |
| Odefsey | RPV/FTC/TAF; 1 tablet daily with food | Alternative initial or switch regimen when baseline viral load, CD4 count, resistance history, food reliability, and acid-suppression needs fit rilpivirine use | Avoids an INSTI; FTC/TAF provides HBV activity | Initial therapy requires appropriate baseline viral-load/CD4 context; PPIs cannot be used; acid-suppression timing and food requirements complicate use. |
| Triumeq | DTG/ABC/3TC; 1 tablet daily | Older/selective alternative rather than a routine leading initial choice | High-barrier DTG; avoids tenofovir | Requires HLA-B*57:01 negativity; no tenofovir-containing HBV backbone; abacavir cardiovascular-risk context may influence selection; not ideal for rapid start. |
Bottom Line
Biktarvy remains the benchmark simple first-line/switch STR for many patients, while Dovato offers an established 2-drug option when genotype, viral load, and HBV status make it appropriate.
Bixlenvo occupies a different niche: it is a switch-only bictegravir + lenacapavir regimen for already-suppressed adults, particularly when regimen complexity or limitations of existing STRs make simplification difficult.
The practical question is not "Is Bixlenvo better than Biktarvy?" but rather whether this suppressed patient needs a simpler regimen that avoids the conventional NRTI backbone or accommodates a treatment history that existing STRs do not fit well.
Before switching: review the complete resistance history, HBV status, prior virologic failures, current medications/interactions, and the Bixlenvo 2-day oral lenacapavir initiation requirement.
Practical Pharmacist Checklist
- HIV-1 RNA <50 copies/mL and stable current ART.
- No known/suspected resistance to bictegravir or lenacapavir.
- No dofetilide, no contraindicated inducer, no not-recommended interacting regimen, and no unresolved Bixlenvo PI interaction concern.
- Complete medication-interaction review, including non-HIV drugs and supplements.
- HBV status reviewed. Bixlenvo does not provide HBV-active therapy; ensure continued appropriate HBV treatment in patients with HIV/HBV coinfection when switching ART.
- Patient understands Days 1 and 2 require oral Sunlenca (lenacapavir), and Bixlenvo-only maintenance starts Day 3.
- Missed-dose plan reviewed, especially the >7-day restart rule.
- Viral-load follow-up planned after switch.
What Makes This Different?
Bixlenvo is not simply "another bictegravir tablet." It combines an INSTI with a capsid inhibitor, contains no conventional NRTI backbone, was studied as a switch strategy in virologically suppressed adults, includes treatment-experienced patients with complex prior regimens, and becomes a once-daily single-tablet maintenance regimen after a two-day oral lenacapavir initiation phase.
Abbreviations & Learner Notes
Backbone usually means the supporting antiretroviral drugs paired with the main anchor drug. In many HIV regimens this is a two-drug NRTI backbone such as tenofovir/emtricitabine or abacavir/lamivudine. Bixlenvo is different because its maintenance regimen pairs bictegravir with lenacapavir and does not include a conventional NRTI backbone.
ART = antiretroviral therapy
STR = single-tablet regimen
INSTI = integrase strand transfer inhibitor
NRTI = nucleoside/nucleotide reverse transcriptase inhibitor
NNRTI = non-nucleoside reverse transcriptase inhibitor
HBV = hepatitis B virus
BIC / LEN = bictegravir / lenacapavir
FTC / TAF / TDF = emtricitabine / tenofovir alafenamide / tenofovir disoproxil fumarate
DTG / 3TC / ABC = dolutegravir / lamivudine / abacavir
DOR / ISL / RPV = doravirine / islatravir / rilpivirine
DRV / COBI / EVG = darunavir / cobicistat / elvitegravir
CrCl = creatinine clearance; PI = protease inhibitor in regimen tables, prescribing information in source labels
Source & Reference
FDA / GILEADU.S. FDA approval announcement — 27 Aug 2026
gilead.com/news/news-details/2026/u-s--fda-approves-gileads-bixlenvo...
FDA / GILEADBixlenvo Prescribing Information — revised 08/2026
gilead.com/-/media/files/pdfs/medicines/hiv/bixlenvo/bixlenvo_pi.pdf
NIHAdult and Adolescent Antiretroviral Guidelines
clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv
FDA / LABELIdvynso prescribing information — revised 04/2026
dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11aaeb53...
primary study records and publications